salvage chemotherapy

sal·vage che·mo·ther·a·py

use of chemotherapy in a patient with recurrence of a malignancy following initial treatment, in hope of a cure or prolongation of life.
Synonym(s): salvage therapy (1)

salvage chemotherapy

A treatment modality consisting of high-dose chemotherapy and bone marrow transplantation for cancer patients who have “failed” one or more protocols. For instance, in Hodgkin lymphoma, 24% of those with long initial remissions survive > 11 years, and thus require further (salvage) therapy (e.g., ABVD—doxorubicin, bleomycin, vinblastine, dacarbazine). Salvage regimens include high-dose chemotherapy (3–10-fold greater than conventional dosage), and may be combined with autologous bone marrow, or peripheral stem cell transplantation. Salvage chemotherapy is problematic as the patients may already be in poor condition, e.g., with severe clinical deterioration; large, bulky, aggressive tumour masses; and multi-drug resistances. Salvage chemotherapy is used in NHL, small cell carcinoma, and Hodgkin lymphoma.

salvage chemotherapy

Oncology A treatment modality consisting of high-dose chemotherapy and BMT, for cancer Pts who have 'failed' one or more protocols. See Heroic therapy.
References in periodicals archive ?
CLAG-M is a salvage chemotherapy regimen consisting of cladribine, cytarabine, filgrastim and mitoxantrone that has become the standard of care at many institutions across the U.
In the trial, 33 percent fewer patients treated in the ADCETRIS containing regimen required subsequent salvage chemotherapy or high dose chemotherapy and transplant compared to the patients treated with ABVD.
DelMar has announced plans to advance VAL-083 into a controlled Phase 3 Study in Temozolomide-Avastin Recurrent GBM to evaluate overall survival versus salvage chemotherapy for GBM patients who have previously failed both temozolomide and bevacizumab and for whom there exists no approved treatment option.
These multicenter, open label trials evaluated patients with cHL who failed ASCT and BV, who were ineligible for ASCT because they were unable to achieve a complete or partial remission after salvage chemotherapy and failed BV, or who failed ASCT and did not receive BV.
All of our patients received CHOP-based chemotherapy with or without rituximab as the first-line treatment; intensified salvage chemotherapy was given to three patients with a PR or disease progression, which resulted in stable disease in two of three patients.
Subsequently, intraperitoneal chemotherapy with paclitaxel was administered followed by salvage chemotherapy with paclitaxel every 21 days.
Incidence of late-relapse germ cell tumour and outcome to salvage chemotherapy.
Because there is no effective second-line or salvage chemotherapy, recurrent disease is associated with a very poor prognosis.
In the AETHERA trial, a patient was considered for brentuximab consolidation therapy if they met at least one of the following risk factors for progression after ASCT: primary refractory Hodgkin's lymphoma; relapsed Hodgkin's lymphoma with an initial remission duration of less than 12 months; or extranodal involvement at the start of pretransplantation salvage chemotherapy [2].
Salvage chemotherapy and testicular radiation led to complete remission when he was 11 years old.
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.
When occurring, platinum-based combination salvage chemotherapy may still achieve long-term remissions in about a half of relapsed disease patients [3, 7].